NWAG
ALNY icon

Net Worth Advisory Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

Net Worth Advisory Group’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-920
Closed -$304K – 413
2026
Q1 		$304K Buy
+920
New +$313K 0.06% 300

Other funds holding ALNY

CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
SSA
Sierra Summit Advisors Incline Village, Nevada $895M AUM 106% 1-Year Est. Return
OIAM
OFI Invest Asset Management Paris, France $10B AUM 48.47% 1-Year Est. Return
II
IFM Investors Melbourne, Australia $15.1B AUM 40.57% 1-Year Est. Return
PSC
Portman Square Capital London, United Kingdom $2.11B AUM 19.71% 1-Year Est. Return
P
PensionDanmark Copenhagen O, Denmark $12B AUM

Net Worth Advisory Group's ALNY Position: Q2 2026 in Review

Net Worth Advisory Group sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2026, closing a stake of 920 shares — an estimated $304K sold.

Net Worth Advisory Group first reported a position in ALNY in Q1 2026 and held it in 1 quarter. The position peaked at $304K in Q1 2026. 104 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Net Worth Advisory Group reported no remaining Alnylam Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Net Worth Advisory Group sold 920 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $304K.
  • Net Worth Advisory Group first reported a position in Alnylam Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Net Worth Advisory Group's Alnylam Pharmaceuticals position peaked at $304K in Q1 2026.
  • 104 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Net Worth Advisory Group's 13F filing for Q2 2026, filed 14 Jul 2026.